BRIAN KELTY: Open Payments
NPI 1124462221 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$879 in 53 payments from 14 companies in 2025. Trend: 2023 $926 · 2024 $727 · 2025 $879
Food & beverage: $879
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $197 |
| Otsuka America Pharmaceutical, Inc. | 12 | $141 |
| Vanda Pharmaceuticals Inc. | 3 | $92 |
| ABBVIE INC. | 4 | $82 |
| Axsome Therapeutics, Inc. | 3 | $79 |
| Collegium Pharmaceutical, Inc. | 4 | $66 |
| Alkermes, Inc. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Sage Therapeutics, LLC | 2 | $31 |
| Neos Therapeutics, LP | 2 | $28 |
Products named: CAPLYTA, REXULTI, FANAPT, VRAYLAR, Auvelity, Jornay PM, ARISTADA, TRINTELLIX.
Industry payments across KY — which companies pay providers there.
